Newest OncoKB updates: May 19, 2023

14 views

Skip to first unread message

unread,

May 19, 2023, 5:33:42 PM5/19/23

to oncok...@googlegroups.com

Dear OncoKB user,

Here are the latest OncoKB updates:

Updated therapeutic implications - new alterations with a level of evidence

Level	Gene	Mutation	Cancer Type	Drug(s)	Evidence
1	RARA	PML-RARA Fusion	Acute Promyelocytic Leukemia	Tretinoin	PMID: 1850498; FDA-approval (1995) of Tretinoin
				Arsenic Trioxide	PMID: 11559723; FDA-approval (2000) of Arsenic Trioxide
				Tretinoin + Arsenic Trioxide	PMID: 23841729; FDA-approval (2000) of Arsenic Trioxide + Tretinoin
2	ERBB2	Amplification	Biliary Tract Cancer	Trastuzumab + Pertuzumab	Inclusion in Biliary Tract Cancer NCCN guidelines (v2.2023)
R2	EGFR	L792H	Non-Small Cell Lung Cancer	Osimertinib	PMID: 28093244, 28625641, 29506987, 29857056, 34526717

Changed Annotation

Gene	Mutation	Cancer Type	Drug(s)	Previous Level	Current Level	Reason
ESR1	Oncogenic ligand-binding domain in-frame insertions or deletions	Breast Cancer	Elacestrant	3A	2	Inclusion in Breast Cancer NCCN guidelines (v4.2023)
KRAS	G12C	Pancreatic Adenocarcinoma	Adagrasib, Sotorasib	3A	2	Inclusion in Pancreatic Cancer NCCN guidelines (v1.2023)

Updated therapeutic implications - Removal of therapies for variants with a level of evidence

Gene	Mutation	Cancer Type	Current Level of Evidence	Drug(s) removed from OncoKB	Drug(s) remaining in OncoKB	Evidence
FGFR2	Fusions	Cholangiocarcinoma	1	Infigratinib	Pemigatinib, Futibatinib	Discontinuation of infigratinib
FGFR1	Amplification	Lung Squamous Cell Carcinoma	3A		Debio1347, Erdafitinib
FGFR1, FGFR2, FGFR3	Oncogenic Mutations	All Solid Tumors	4		Debio1347, Erdafitinib, AZD4547

As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you.

The OncoKB Team

--
You received this message because you are subscribed to the Google Groups "oncokb-news" group.
To unsubscribe from this group and stop receiving emails from it, send an email to oncokb-news...@googlegroups.com.
To view this discussion on the web visit https://groups.google.com/d/msgid/oncokb-news/CAESvFs9rtDE0z069B%2BT2b9n5z4AG3vmizZmviNiLTbdjY%2BZJfg%40mail.gmail.com.

*** Only open attachments or links from trusted senders. Report phishing to inf...@mskcc.org ***